1. A piezoelectric thin film elemental device comprising: a lower electrode; a piezoelectric thin film; and an upper electrode on a silicon substrate, with the piezoelectric thin film having a (K1\u2212xNax)NbO3 thin film of a perovskite structure, expressed by a compositional formula (K1\u2212xNax)NbO3 (0<x<1), and a ratio of an out-of-plane directional lattice constant c to an in-plane directional lattice constant a of the (K1\u2212xNax)NbO3 thin film set in a range of 0.0980\u2266ca\u22661.0100.
2. The piezoelectric thin film elemental device according to claim 1, wherein when there are a plurality of layers of (K1\u2212xNax)NbO3 (0<x<1) thin films in the piezoelectric thin film, at least the same composition layer of the thickest (K1\u2212xNax)NbO3 thin film out of these plurality of layers is set within the range of 0.0980\u2266ca\u22661.0100.
3. The piezoelectric thin film elemental device according to claim 1, wherein the (K1\u2212xNax)NbO3 thin film is preferentially-oriented in a (001) plane direction.
4. The piezoelectric thin film elemental device according to claim 1, wherein the (K1\u2212xNax)NbO3 thin film is formed by an RF magnetron sputtering technique.
5. The piezoelectric thin film elemental device according to claim 1, wherein the lower electrode is formed of Pt or Au.
6. The piezoelectric thin film elemental device according to claim 5, wherein the lower electrode formed of Pt is preferentially-oriented in a (111) plane direction.
7. The piezoelectric thin film elemental device according to claim 1, wherein the lower electrode is formed by an RF magnetron sputtering technique.
8. The piezoelectric thin film elemental device according to claim 1, wherein a SiO2 film is formed on a surface of the silicon substrate.
9. The piezoelectric thin film elemental device according to claim 1, wherein a Ti layer is provided between the silicon substrate and the lower electrode.
10. The piezoelectric thin film elemental device according to claim 1, wherein a stress relaxation layer having a perovskite structure and having a lattice constant different from that of the (K1\u2212xNax)NbO3 thin film is provided between the lower electrode and the (K1\u2212xNax)NbO3 thin film.
11. The piezoelectric thin film elemental device according to claim 10, wherein the stress relaxation layer is formed of any one of LaNiO3, SrTiO3, LaAlO3, YAlO3, BaZrO3, BaSnO3, BaMnO3.
12. The piezoelectric thin film elemental device according to claim 1, wherein at least one kind of Ta, Li, Sb is added to the (K1\u2212xNax)NbO3 thin film.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of the formula (I) or pharmaceutically acceptable salt thereof,
wherein
X1 and X2 each is independently lower alkylene;
X3 is \u2550CH2, \u2550CHF or \u2550CF2;
R1 is selected from the group consisting of:
(a) R4O\u2014 wherein R4 is H, lower alkyl optionally substituted with substituent \u03b1, lower alkenyl, aryl optionally substituted with substituent \u03b1, or heteroaryl optionally substituted with substituent \u03b1,
(b) R5R6N\u2014 wherein R5 and R6 each is independently H, lower alkyl, lower alkanoyl, (lower alkyl)sulfonyl, arylsulfonyl optionally substituted with substituent \u03b1, or heteroarylsulfonyl optionally substituted with substituent \u03b1,
(c) R7N\u2550 wherein R7 is H, hydroxy, lower alkoxy, aryl(lower alkyl)oxy optionally substituted with substituent \u03b1 on the aryl group, or heteroaryl(lower alkyl)oxy optionally substituted with substituent \u03b1 on the heteroaryl group,
(d) saturated heterocyclyl;
(e) carboxy;
(f) sulfonic acid;
(g) halogen; and
(h) oxo;
R2 and R3 are independently H or lower alkyl;
n is 0,1,2,3 or4 wherein said substituent \u03b1 is selected from the group consisting of lower alkyl, hydroxyl, lower alkoxy, aryloxy optionally substituted with substituent \u03b2, heteroaryloxy optionally substituted with substituent \u03b2, amino, (lower alkyl) amino, di(lower alkyl)amino, arylamino optionally substituted with substituent \u03b2 on the aryl group, heteroarylamino optionally substituted with substituent \u03b2 on the heteroaryl group, (lower alkyl) sulfonylamino, halogenated(lower alkyl)sulfonylamino, arylsulfonylamino optionally substituted with substituent \u03b2 on the aryl group, heteroarylsulfonylamino optionally substituted with substituent \u03b2 on the heteroaryl group, di(lower alkyl) aminosulfonylamino, oxo, imino, hydroxyimino, (lower alkyl)sulfonyl, arylsulfonyl optionally substituted with substituent \u03b2, heteroarylsulfonyl optionally substituted with substituent \u03b2, heteroarylsulfonyl optionally substituted with substituent \u03b2, lower alkanoyl, halogen, cyano, nitro and carboxy; and wherein the said substituent \u03b2 is selected from the group consisting of lower alkyl, hydroxyl, lower atkoxy, amino, (lower alkyl)amino, di(lower alkyl)amino, (lower alkyl)amino, (lower alkanoyl)amino, halogen, cyano, nitro, and carboxy.
2. The compound of claim 1, wherein the said substituent \u03b1 is selected from the group consisting of:
lower alkyl,
hydroxy,
lower alkoxy,
aryloxy optionally substituted with substituent \u03b2,
heteroaryloxy optionally substituted with substituent \u03b2,
amino,
(lower alkyl)amino,
di(lower alkyl)amino,
arylamino optionally substituted with substituent \u03b2 on the aryl group,
heteroarylamino optionally substituted with substituent \u03b2 on the heteroaryl group,
(lower alkyl)sulfonylamino,
halo genated(lower alkyl)sulfonylamino,
arylsulfonylamino optionally substituted with substituent \u03b2 on the aryl group,
heteroarylsulfonylamino optionally substituted with substituent \u03b2 on the heteroaryl group,
di(lower alkyl)aminosulfonylamino,
oxo,
imino,
hydroxyimino,
(lower alkyl)sulfonyl,
arylsulfonyl optionally substituted with substituent \u03b2,
heteroarylsulfonyl optionally substituted with substituent \u03b2,
lower alkanoyl,
halogen,
cyano,
nitro and
carboxy;
the said substituent \u03b2 is selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, amino, (lower alkyl)amino, di(lower alikyl)amino, (lower alkanoyl)amino, halogen, cyano, nitro and carboxy.
3. The compound of claim 2, wherein R1 is selected from the group consisting of hydroxy, lower alkoxy optionally substituted with hydroxy(s), lower alkenyloxy, amino optionally substituted with substituent lower alkanoyl, halogen, oxo, imino and hydroxyimino.
4. The compound of claim 3, wherein R1 is selected from the group consisting of hydroxy, amino and halogen.
5. The compound of claim 4, wherein R1 is hydroxy.
6. The compound of claim 2, wherein R1 is R4O\u2014 wherein R4 is lower alkyl optionally substituted with substituent \u03b1 aryl optionally substituted with substituent \u03b1, or heteroaryl optionally substituted with substituent \u03b1,
the said substituent a is selected from the group consisting of hydroxy, arylamino, heteroarylamino, arylsulfonylamino, heteroarylsulfonylamino, oxo, imino, hydroxyimino, lower alkanoyl, halogen, cyano, nitro and carboxy.
7. The compound of claim 2, wherein R1 is lower alkoxy optionally substituted with substituent \u03b1,
the said substituent \u03b1 is selected from the group consisting of hydroxy, lower alkoxy, amino, (lower alkyl)amino, di(lower alkyl)amino, (lower alkyl)sulfonylamino, halogenated(lower alkyl)sulfonylamino, di(lower alkyl)aminosulfonylamino, oxo, imino, hydroxyimino and carboxy.
8. The compound of claim 2, wherein R1 is lower alkoxy optionally substituted with substituent \u03b1,
the substituent \u03b1 is selected from the group consisting of heteroarylamino optionally substituted with substituent \u03b2 on the heteroaryl group, heteroarylsulfonylamino optionally substituted with substituent \u03b2 on the heteroaryl group and oxo;
the said substituent \u03b2 is selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkanoyl, halogen, cyano, nitro and carboxy.
9. The compound of claim 2, wherein R1 is selected from the group consisting of aryloxy optionally substituted with substituent \u03b1, heteroaryloxy optionally substituted with substituent \u03b1, and saturated heterocyclyl;
the said substituent a is selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkanoyl, halogen, cyano, nitro and carboxy.
10. The compound ofclaim 9, wherein R1 is selected from the group consisting of aryloxy optionally substituted with substituent \u03b1, and heteroaryloxy optionally substituted with substituent \u03b1,
the said substituent a is selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkanoyl, halogen, cyano, nitro and carboxy.
11. The compound of claim 2, wherein R1 is R5R6N\u2014 wherein R5 and R6 each is independently (lower alkyl)sulfonyl, arylsulfonyl optionally substituted with substituent \u03b1, or heteroarylsulfonyl optionally substituted with substituent \u03b1;
the said substituent a is selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkanoyl, halogen, cyano, nitro and carboxy.
12. The compound of claim 2, wherein R1 is R7N\u2550 wherein R7 is H, hydroxy, lower alkoxy, aryl(lower alkyl)oxy optionally substituted with substituent \u03b1 on the aryl group;
the said substituent \u03b1 is selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkanoyl, halogen, cyano, nitro and carboxy.
13. The compound of claim 1, wherein X1 and X2 each is independently (C1\u2013C4)alkylene.
14. The compound of claim 1, wherein X1 and X2 each is independently (C1\u2013C2)alkylene.
15. The compound of claim 1, wherein X3 is\u2550CH2 or\u2550CHF.
16. The compound ofclaim 1, wherein X3 is\u2550CH2.
17. The compound of claim 1, wherein R2 and R3 each is independently H or (C1\u2013C4)alkyl.
18. The compound of claim 1, wherein R2 and R3 each is independently H or (C1\u2013C2)alkyl.
19. The compound of claim 1, wherein R2 and R3 are H.
20. The compound of claim 1, wherein n is 1, 2, 3 or 4.
21. The compound of claim 1, wherein n is 1 or 2.
22. The compound of claim 1, wherein n is 1.
23. The compound of claim 1, selected from:
(2S)- 1-{(1S,3S,4S,5S,6R)-5,6-Dihydroxy-2-azabicyclo2.2.2oct-3-ylcarbonyl}-2-pyrrolidinecarbonitrile hydrochloride;
(2S)- 1- {(1S,3S,4S,5R)-5-Hydroxy-2-azabicyclo2.2.2oct-3-ylcarbonyl}-2-pyrrolidinecarbonitrile hydrochloride;
(2S)- 1- {(1R,3S,4S,6R)-6-Hydroxy-2-azabicyclo 2.2.1hept-3-ylcarbonyl}-2-pyrrolidinecarbonitrile hydrochloride;
(2S)- 1- {(1R,3S,4S,6S)-6-Hydroxy-2-azabicyclo2.2. 1hept-3-ylcarbonyl}-2-pyrrolidinecarbonitrile hydrochloride;
(2S)- 1- {(1R,3S,4S,6R)-6-(2-Hydroxyethoxy)-2- azabicyclo2.2. 1 hept-3-ylcarbonyl}-2- pyrrolidinecarbonitrile hydrochloride;
(2S)- 1- {(1R,3S,4S,6Z)-6-Hydroxyimino-2-azabicyclo2.2.1hept-3-ylcarbonyl}-2-pyrrolidinecarbomtrile hydrochloride;
N-((1R,3S,4S,6R)-3- {(2S)-2-Cyano- 1-pyrrolidinylcarbonyl}-2-azabicyclo2.2.1hept-6-yl)acetamide hydrochloride;
(2S)- 1- {(1R,3S,4R,6R)-6-Amino-2-azabicyclo2.2.1hept-3-ylcarbonyl}-2-pyrrolidinecarbonitrile dihydrochloride;
(2S)- 1- {(1R,4R,5R,7S)-4-Hydroxy-6-azabicyclo3.2.1oct-7-ylcarbonyl}-2-pyrrolidinecarbonitrile hydrochloride.
24. A method for producing the compound of formula (I) of claim 1, comprising deprotecting the following compound of formula (IV):
wherein
R1, is R1 protected not to inhibit this reaction, if needed;
Pro is protective group of amino group.
25. A pharmaceutical composition comprising a compound of claim 1 as an active ingredient, in association with a pharmaceutically acceptable carrier or excipient.
26. A method for treating Non-Insulin Dependent Diabetes Mellitus (\u201cNIDDM\u201d) which comprises administering an effective amount of the compound of claim 1 to human beings or animals.
27. A commercial package comprising the pharmaceutical composition containing the compound identified in claim 1 and a written matter associated therewith, wherein the written matter states that the compound (I) can or should be used for treating Non-Insulin Dependent Diabetes Mellitus (\u201cNIDDM\u201d).